Anticancer Drugs Copanlisib Oncology Pharmacology Physiotherapy

Copanlisib (Mechanism of Action)

In this article we will discuss Copanlisib (Mechanism of Action)

In this article, we will discuss Copanlisib (Mechanism of Action). So, let’s get started.

Mechanism of Action

Copanlisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B cells. Copanlisib has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines. Copanlisib inhibits several key cell-signaling pathways, including B-cell receptor (BCR) signaling, CXCR12 mediated chemotaxis of malignant B cells, and NFκB signaling in lymphoma cell lines.


At 60 mg (or 0.8 mg/kg) of Copanlisib dose, the elevation of plasma glucose was associated with higher copanlisib exposure.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.